EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion

Quentin Van Thillo iD, Barbara Dewaele, Jolien De Bie, Lucienne Michaux, Timothy Devos, Peter Vandenberghe iD

British Journal of Haematology · 2023

DOI: 10.1111/bjh.18849 ↗

Kurz gefasst

Fallbericht in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Quentin Van Thillo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, University Hospitals Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Myeloproliferative Disorders, Hypereosinophilic Syndrome, Lymphoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fusions involving receptor tyrosine kinases (RTKs) play a crucial role in the development of myeloid/lymphoid neoplasms with eosinophilia (M/LNeo),1 a separate disease category in the 2022 WHO and ICC classifications.2,3 Of these, PDGFRAand PDGFRBrearranged cases are exquisitely sensitive to treatment with the tyrosine kinase inhibitor (TKI) imatinib.4– 6 Hence, a correct diagnosis of the underlying molecular aberration is of utmost importance for adequate treatment, yet remains challenging, due to the rarity of these diseases, and the many different translocation partners for these RTKs.1 Here, we present a case, initially diagnosed as iHES, in which analysis with updated molecular techniques led to the identification of the second case of a myeloid/lymphoid neoplasm with a t(5;12)(q32;q23) and a SART3::PDGFRB fusion gene. In 2011, a 30yearold man presented with a deep vein thrombosis in the right axillary and subclavian veins. A blood test showed hyperleucocytosis (13 100/μL) with 39% eosinophils and circulating myeloid precursor cells, as well as increased vitamin B12 and tryptase (Supplementary Table S1). Bone marrow cytology showed a central eosinophilia of 38% with dysplastic myeloid precursors and eosinophils. The karyotype was normal (46,XY[10]), with a subtle difference in length of 12q interpreted as a fragile site at 12q24. Fluorescence in situ hybridisation (FISH) with a breakapart PDGFRA probe showed a normal hybridisation pattern. In addition, polymerase chain reaction (PCR) did not detect BCR::ABL1 or FIP1L1::PDGFRA fusion transcripts, nor the JAK2 p.V617F mutation. Shortly afterwards, the patient developed night sweats, weight loss and symptoms of hyperviscosity, with eosinophilia of 30 850/μL. On ultrasound, the spleen measured 26 cm. Electrocardiogram (ECG) showed new Twave inversions in V3V4 and serum troponin levels were increased (300– 500 ng/L, ≤14 ng/L). Magnetic resonance imaging (MRI) revealed an apical thrombus and subendocardial enhancement of the myocardium, findings compatible with Loeffler's endocarditis. Subsequently, the patient developed an acute left hemiplegia with diffuse ischemia in the cerebrum and cerebellum with haemorrhagic transformation on MRI. The diagnosis of idiopathic hypereosinophilic syndrome was made. Initial therapy consisted of hydroxyurea and highdose methylprednisolone, along with low molecular weight heparin. Vincristine and cyclophosphamide were administered once, and, 2 days after hemiplegia development, treatment with imatinib 400 mg was initiated. This was promptly followed by a resolution of the eosinophilia and normalisation of the blood count (Figure 1). After discharge of the patient, imatinib was continued and methylprednisolone was gradually tapered to full stop. The patient fully recovered and was followed at regular intervals at our outpatient clinic. Afterwards, the dose of imatinib was gradually lowered to 200 mg with continuing haematological remission. In view of several recent reports of cytogenetically cryptic fusions of tyrosine kinase genes other than PDGFRA,7 we decided to reopen this case and performed FISH for PDGFRB and FGFR1 on a stored cytogenetic pellet. FISH revealed a split signal of PDGFRB/5q32. Review of the original karyotype led to a revised karyotype: 46,XY,t(5;12) (q32;q23). Optical genome mapping (OGM) using the Saphyr Received: 13 March 2023 | Accepted: 25 April 2023

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloproliferative DisordersHypereosinophilic SyndromeLymphomaHumansReceptor, Platelet-Derived Growth Factor betaOncogene Proteins, FusionAntigens, NeoplasmRNA-Binding Proteins

Substanzen

Receptor, Platelet-Derived Growth Factor betaOncogene Proteins, FusionSART3 protein, humanAntigens, NeoplasmRNA-Binding ProteinsPDGFRB protein, human

Autor:innen und Institutionen

  • Department of Haematology, University Hospitals Leuven, Leuven, Belgium.
  • Department of Human Genetics, KU Leuven, Leuven, Belgium.
  • Department of Microbiology and Immunology, Laboratory of Molecular Immunology (Rega Institute), KU Leuven, Leuven, Belgium.

ORCID-Profile: Quentin Van Thillo, Peter Vandenberghe

Zitieren

APA

Van Thillo, Q., Dewaele, B., De Bie, J., Michaux, L., Devos, T., & Vandenberghe, P. (2023). Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion. British Journal of Haematology. https://doi.org/10.1111/bjh.18849

Vancouver

Van Thillo Q, Dewaele B, De Bie J, Michaux L, Devos T, Vandenberghe P. Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion. British Journal of Haematology. 2023. doi:10.1111/bjh.18849

BibTeX
@article{VanThillo2023,
  author = {Van Thillo, Quentin and Dewaele, Barbara and De Bie, Jolien and Michaux, Lucienne and Devos, Timothy and Vandenberghe, Peter},
  title = {Revisiting a case of idiopathic hypereosinophilic syndrome with novel molecular techniques identifies a second case of a myeloid/lymphoid neoplasm with a SART3::PDGFRB fusion},
  journal = {British Journal of Haematology},
  year = {2023},
  doi = {10.1111/bjh.18849}
}
Kostenlos starten →